Case report: The use of netarsudil to improve corneal edema after laser peripheral iridotomy and Descemet's membrane endothelial keratoplasty
- PMID: 33997467
- PMCID: PMC8094567
- DOI: 10.1016/j.ajoc.2021.101087
Case report: The use of netarsudil to improve corneal edema after laser peripheral iridotomy and Descemet's membrane endothelial keratoplasty
Abstract
Purpose: To report a case in which netarsudil ophthalmic solution 0.02% improved refractory corneal edema after laser peripheral iridotomy (LPI) and Descemet's membrane endothelial keratoplasty (DMEK).
Observations: A 63-year-old female presented with decreased vision due to corneal edema secondary to iatrogenic endothelial cell loss from previous YAG and argon laser peripheral iridotomy. Initial treatment with topical sodium chloride 5% solution was unsuccessful in resolving the edema. As a result, topical netarsudil was initiated off-label. Improvement in corneal thickness and visual acuity was noted, but after a few months, the left eye decompensated with worsening edema. Cataract surgery with DMEK was performed. Surgery was prolonged and intraoperative floppy iris was encountered. Post-operatively, the patient's best-corrected visual acuity (VA) fluctuated between 20/30 to 20/70 with persistent corneal edema. The central corneal thickness (CCT) ranged from 758 to 779 three months after surgery. Topical netarsudil was started again off-label for cornea edema once nightly. Over the next two months, visual acuity and CCT improved to 20/25 and 650, respectively. Stabilization of visual acuity and cornea edema has been maintained for eight months after initiation of topical netarsudil.
Conclusions: Netarsudil, a commercially available rho-kinase inhibitor, may be an effective, non-invasive adjunctive therapy for refractory corneal edema. Our case demonstrates improvement in BCVA and CCT using topical netarsudil, which has been maintained without any vision threatening side effects.
Keywords: Corneal edema; DMEK; LPI; Netarsudil; Rho-kinase inhibitors.
© 2021 The Authors.
Conflict of interest statement
No conflicts of interest to report.
Figures



Similar articles
-
Reticular Epithelial Edema: An Uncommon Side Effect of ROCK/NET Inhibitor Netarsudil.J Glaucoma. 2020 Nov;29(11):e124-e126. doi: 10.1097/IJG.0000000000001636. J Glaucoma. 2020. PMID: 32826765
-
Corneal Graft Rejection after Descemet's Membrane Endothelial Keratoplasty with Peripheral Anterior Synechiae.Case Rep Ophthalmol. 2022 Jan 31;13(1):17-22. doi: 10.1159/000520877. eCollection 2022 Jan-Apr. Case Rep Ophthalmol. 2022. PMID: 35221975 Free PMC article.
-
Phase 2, Randomized, Open-Label Parallel-Group Study of Two Dosing Regimens of Netarsudil for the Treatment of Corneal Edema Due to Fuchs Corneal Dystrophy.J Ocul Pharmacol Ther. 2022 Dec;38(10):657-663. doi: 10.1089/jop.2022.0069. Epub 2022 Nov 3. J Ocul Pharmacol Ther. 2022. PMID: 36327101 Free PMC article. Clinical Trial.
-
Infectious interface keratitis (IIK) following lamellar keratoplasty: A literature review.Ocul Surf. 2019 Oct;17(4):635-643. doi: 10.1016/j.jtos.2019.08.001. Epub 2019 Aug 12. Ocul Surf. 2019. PMID: 31415815
-
The Role of Rho Kinase Inhibitors in Corneal Diseases.Drug Des Devel Ther. 2024 Jan 19;18:97-108. doi: 10.2147/DDDT.S435522. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 38264539 Free PMC article. Review.
Cited by
-
Ocular effects of Rho kinase (ROCK) inhibition: a systematic review.Eye (Lond). 2024 Dec;38(18):3418-3428. doi: 10.1038/s41433-024-03342-4. Epub 2024 Sep 16. Eye (Lond). 2024. PMID: 39285241
-
Reticular corneal epithelial edema with topical netarsudil.Oman J Ophthalmol. 2023 Feb 21;16(1):94-97. doi: 10.4103/ojo.ojo_2_22. eCollection 2023 Jan-Apr. Oman J Ophthalmol. 2023. PMID: 37007228 Free PMC article.
-
ROCK Inhibitors in Corneal Diseases and Glaucoma-A Comprehensive Review of These Emerging Drugs.J Clin Med. 2023 Oct 25;12(21):6736. doi: 10.3390/jcm12216736. J Clin Med. 2023. PMID: 37959203 Free PMC article. Review.
-
Two pediatric cases of reticular corneal epithelial edema associated with netarsudil.Am J Ophthalmol Case Rep. 2022 Jun 28;27:101638. doi: 10.1016/j.ajoc.2022.101638. eCollection 2022 Sep. Am J Ophthalmol Case Rep. 2022. PMID: 35813588 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials